# Novo Nordisk Develops Oral Ozempic for Type 2 Diabetes
Novo Nordisk is advancing an oral formulation of semaglutide, the active ingredient in the injectable diabetes medication Ozempic. The pill version could expand access to a treatment that has transformed diabetes care over the past several years.
The injectable Ozempic has become one of the most prescribed medications for type 2 diabetes because it effectively lowers blood sugar and helps patients lose weight. Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar and appetite. The injectable version requires weekly injections, which creates a barrier for some patients who prefer oral medications or struggle with injection anxiety.
An oral tablet addresses these practical concerns. Patients could take the medication daily at home without needles or healthcare provider visits for injections. This convenience factor matters for medication adherence. Studies show patients often skip doses of injected medications more frequently than oral ones.
The development of an oral semaglutide aligns with broader industry trends toward patient-centered drug delivery. Other pharmaceutical companies are also exploring pill versions of GLP-1 receptor agonists to capture market share in the growing diabetes treatment space.
Type 2 diabetes affects over 37 million Americans, and injectable GLP-1 drugs have become first-line treatments for many patients, particularly those who are overweight or obese. The oral formulation could reach patients who have delayed treatment because of injection concerns or those in regions with limited access to injection-based therapies.
The pill still requires regulatory approval before becoming available to patients. Novo Nordisk will need to demonstrate that the oral form delivers comparable efficacy and safety to the injection. Absorption challenges with oral peptide drugs historically posed manufacturing hurdles, though recent advances in form